Companies / BB1

BLINKLAB LIMITED

ASX:BB1Health Care Equipment & Services
153.3M shares on issueASX (delayed) · as of 28 July 2026$0.59price · delayed$90.4Mmarket cap · indicative
D
Dilution grade

Share count grew 150% in 24 months; 6 cash raises in 24 months; options/rights overhang 60% of shares

Cash runway6.5 quarters of funding
Share-count growth (24m)150.1%
Raise cadence (24m)6 cash raises
Options & rights overhang60.1% of shares
In-the-money supply28.9% of shares
Pending proposed issuesnone

BLINKLAB LIMITED's ordinary share count grew 150.1% between December 2024 and July 2026, to 153M shares. The company raised capital six times over the period for total disclosed proceeds of A$43.1M, most recently a A$17.7M placement in April 2026. Options and rights on issue could convert into 92M new shares, equal to 60.1% of the current share count, of which 29% are in the money; the nearest expiry falls in September 2026. At the June 2026 quarter the company reported A$17.1M in available cash, about 6.5 quarters of funding at its recent spending rate. No proposed securities issues (Appendix 3B) are pending.

AI-generated summary of this page's cited filings · updated 28 July 2026
Email me when this grade changes
Alerts are coming soon — this opens a pre-filled email that puts you on the list.
60.1%
Max option dilution
28.9%
ITM option dilution
2
Raises · last 12 months
6.5 qtrs
Cash cover · over 4 quarters

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 153.3M per ASX (delayed) (28 July 2026).
110.5M126.2M141.9MDec 24Sept 25July 26Cash raise · 13 Apr 2026Cash raise · 13 Apr 2026Cash raise · 2 July 2025Cash raise · 30 June 2025Cash raise · 28 Apr 2025Cash raise · 27 Feb 2025

Cash runway

6.5 qtrs
More than four quarters of funding at the recent spend rate.
$17.1M available cash at quarter ended 30 June 2026 · Runway is computed from Appendix 4C/5B filings and announced raise proceeds.
Paid plan
Cash runway history
Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 30 June 2026.
Join the waitlist

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityTotal on issue afterSource
13 July 20262A · quoted issueBB1 : ORDINARY FULLY PAID153.0MAppendix 2A
13 July 20262A · quoted issueBB1 : ORDINARY FULLY PAID153.1MAppendix 2A
13 July 20263G · unquotedBB1 : ORDINARY FULLY PAID152.9MAppendix 3G
1 July 20263G · unquotedBB1 : ORDINARY FULLY PAID152.9MAppendix 3G
22 Apr 20262A · quoted issueBB1 : ORDINARY FULLY PAID152.9MAppendix 2A
Paid plan
Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Join the waitlist

Capital raises

6 cash raises in the last 24 months · 2 in the last 12 months

$17.7M
Placement
13 Apr 2026 COMPLETE
Paid plan
Full raise history
Issue price, discount, brokers, purpose and tranche detail for every raise on record.
Join the waitlist

Pending proposed issues

No proposed issues (Appendix 3B) currently pending.

Options & convertible securities

60.1%
Total overhang · of current shares
28.9%
In the money · at current price
92.1M
Potential new shares
Sept 2026
Nearest expiry
Paid plan
Per-line options & expiry cliffs
Each option line — code, strike, expiry, quantity and ITM value — plus the expiry-cliff chart.
Join the waitlist

Director dealings

DateDirectorTypeSharesOptionsValueSource
13 July 2026Mr Brian LeedmanBuy83k500k$54k3Y notice
13 July 2026Dr Anton UvarovBuy83k500k$54k3Y notice
13 July 2026Dr Richard HopkinsBuy52k500k$34k3Y notice
Paid plan
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Join the waitlist

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Sign up free — coming soon

Latest announcements

26 July 2026BlinkLab to Present at TechKnow Invest Roadshow
26 July 2026$PQuarterly Activities/Appendix 4C Cash Flow Report
14 July 2026Change of Director's Interest Notice x4
13 July 2026Company Update on Clinical Development Programs
13 July 2026Section 708A Notice
13 July 2026Notification regarding unquoted securities - BB1
13 July 2026Application for quotation of securities - BB1
13 July 2026Application for quotation of securities - BB1
1 July 2026Notification regarding unquoted securities - BB1
25 June 2026European ADHD Study Update
25 June 2026Results of General Meeting
17 June 2026BB1 Granted Foundational U.S. Patent
15 June 2026BB1 Partners with ESPOCH on Large-Scale Multicenter Program
22 May 2026Letter to Shareholders & Proxy Form
22 May 2026Notice of General Meeting & Proxy Form
18 May 2026Therapy Evaluation for Neurodevelopmental Conditions
13 May 2026BB1 to present at Stocks in the Vines Investor Access Day
29 Apr 2026$PQuarterly Activities/Appendix 4C Cash Flow Report
22 Apr 2026Section 708A Notice
22 Apr 2026Application for quotation of securities - BB1

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.